Abstract 3252
Background
Immune checkpoint inhibitors (ICI) have improved clinical outcome for many patients with advanced cutaneous malignant melanoma (CMM) during the last decade. The magnitude and duration of response vary considerably between patients. Predictive biomarkers to identify patients that will benefit from treatment can increase efficacy, diminish side effects and costs. Our aim is to identify predictive biomarkers in tumors samples from patients with advanced CMM receiving ICI.
Methods
Patients with advanced CMM at Karolinska University Hospital, Stockholm, starting therapy with ICI were invited to participate in our study. After signing informed consent a pre-treatment fine needle or core biopsy was taken from an accessible metastasis. RNA was extracted to perform targeted RNA sequencing using the Ion AmpliSeq Transcriptome Human Gene Expression Kit for RefSeq genes. Partek Genomics Suite® software was applied to find differentially expressed genes and correlate the data with therapy response and progression free survival (PFS).
Results
Nineteen patients were included between September2013 and August2017, 8 female and 11 male. The median age was 70 years old (range 49 – 84). All patients had metastatic disease (13 M1c, 4 M1b, 2 M1a). ICI was first-line treatment for 16 patients. Nivolumab or pembrolizumab was given to 17 patients and two received ipilimumab. Five patients had partial response, 3 stable disease and 7 complete response whereas 4 had progressive diasease. Median PFS was 10 months (range 1,2 – 62 months, 6 patients still responding). High expression of a subset of genes playing a role for DNA replication, genes involved in chromatin remodeling and cell cycle were significantly associated with shorter PFS. The correlation between low expression of interferon gamma signature genes and poorer treatment outcome was confirmed in our study.
Conclusions
Our findings suggest that genes involved in the regulation of DNA replication, chromatin remodeling and cell cycle may influence the long-term response to ICI.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Karolinska University Hospital and Karolinska Institute.
Funding
The Swedish Cancer Society, the Cancer Research Funds of Radiumhemmet and Knut and Alice Wallenberg foundation. We aknowledge support of the Science for Life Laboratory, National Genomics Infrastructure (NGI)/Uppsala, Genome Center and UPPMAX for providing assistance in massive parallel sequencing and computational infrastructure (work funded by RFI/VR and Scilife, Sweden).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3361 - Providing a nurse-led telephone intervention for patients treated with oral anticancer medication: symptom management and adherence monitoring
Presenter: Etienne Minvielle
Session: Poster Display session 3
Resources:
Abstract
3937 - Chronological evaluation of health-related quality of life and physical symptoms in postoperative pancreatic cancer patients up to 12 months
Presenter: Naoko Sato
Session: Poster Display session 3
Resources:
Abstract
5620 - Understanding the patients’ Experiences of Radiation Therapy: A Qualitative Study on Prostate Cancer Patients
Presenter: Sakarias Johansson
Session: Poster Display session 3
Resources:
Abstract
1792 - Effect of Kegel exercises on prevention of urinary and fecal incontinence in patients with prostate cancer undergoing radiotherapy
Presenter: Aydan Uravylioglu
Session: Poster Display session 3
Resources:
Abstract
2169 - The Meaning of Responsibility – a Secondary Analysis of Patients and Caregivers Calls to an Oncology Emergency Telephone
Presenter: Heidi Jacobsen
Session: Poster Display session 3
Resources:
Abstract
4587 - Cognitive function changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Elif Dil
Session: Poster Display session 3
Resources:
Abstract
1981 - Prevention of dental complications in patients with multiple myeloma (MM) receiving bisphosphonates treatment
Presenter: CESCA PUIGMARTI
Session: Poster Display session 3
Resources:
Abstract
2725 - Safety profile of oral netupitant/palonosetron in hematopoietic stem cell transplantation recipients.
Presenter: Marina Bosch - Damas
Session: Poster Display session 3
Resources:
Abstract
5112 - Symptomatic and toxicity management of cancer patients using a telephone support model led by the oncology nurse
Presenter: Gemma Simó
Session: Poster Display session 3
Resources:
Abstract
1365 - Symptom cluster of fatigue, sleep disturbance and depression and its impact on quality of life among Chinese breast cancer patients undergoing adjuvant chemotherapy: A cross-sectional study
Presenter: Xiaole HE
Session: Poster Display session 3
Resources:
Abstract